At the American Association for Cancer Research (AACR) Annual Meeting 2026 in San Diego, SK Life Science Labs, a subsidiary of SK Biopharmaceuticals, unveiled three posters highlighting advancements in its targeted protein degradation (TPD) pipeline.
Core Research Programs: The company’s technology leverages the body’s innate ubiquitin-proteasome system (UPS) to selectively eliminate oncogenic proteins. The newly released data focus on two promising programs:
-
Selective p300 Degraders: The findings demonstrate deep anti-tumor activity in CBP mutant cancers and p300-dependent models, such as prostate cancer and multiple myeloma. A key advantage is the high selectivity that avoids degrading the closely related CBP protein, potentially reducing hematologic toxicity compared to traditional dual-inhibition approaches.
-
Next-generation PRMT5 Degraders: This program shows rapid and potent degradation of PRMT5. Unlike earlier inhibitors, this degradation mechanism eliminates both the catalytic and non-catalytic functions of the target, offering a solution to the efficacy limitations encountered by first- and second-generation inhibitors.
Vision and Roadmap: Currently, the p300 degrader program is advancing through IND-enabling studies. By integrating an AI-enabled target ID platform and the MOPED™ molecular glue screening platform, SK Life Science Labs is accelerating the discovery of treatments for targets previously considered “undruggable.” Experts view this data as a significant step toward developing high-precision therapies with improved safety profiles for cancer patients.